The principal goal of the Developmental Research Program is to fund promising early stage projects that address important translational objectives in prevention, early detection, and therapy of pancreatic carcinoma. Our principal intent for Developmental Research Program is to bring novel translational research projects to the SPORE program. Key elements that determine priority in this program are innovation, novelty, and potential for success in translational pancreatic cancer research. All Developmental Funds will be awarded by competition based on submission of a NIH-style pilot project application. There is a requirement for clear evidence that the proposed project shows potential of developing into a larger research project that will involve human intervention for pancreatic cancer (diagnostic or therapeutic). We will have available a minimum of $175,000 a year ($100,000 from the SPORE grant and $75,000 a year in matching funds from the UNMC/Eppley Cancer Center), which will be used to fund 2 projects. We will accept applications from single investigators for focused projects with budgets of up to $87,500 or larger collaborative projects involving two or more investigators with budgets of up to $175,000. Proposals are received and processed by the Administrative Core. Once a year, a request for proposals (RFP) is developed by the Principal Investigator and distributed to all faculty at the University of Nebraska Medical Center, Creighton University, the University of Nebraska at Omaha, the University of Nebraska at Lincoln, University of Nebraska at Kearny, collaborating faculty at other institutions, and faculty members at other Institutions who have contacted us or have been identified by the SPORE Scientific Council, Internal Advisory Board, or External Advisory Committee as potential collaborators on existing projects or developers of important new SPORE projects related to pancreatic cancer. Two types of applications will be solicited. Applications from single investigators for focused projects with budgets of up to $87,500 per year, or larger collaborative translational projects involving two or more investigators with budgets of up to $175,000 per year. Applications are reviewed by a study section comprised of the Internal Advisory Board, members of the SPORE program who are not in conflict, selected scientists and clinicians from the UNMC Eppley Cancer Center. Final selection of the funded applications is made by the External Advisory Board, who acts as a Advisory Council, in consultation with Dr. Brattain and Dr. Grem, who are the administrative leaders of the Developmental Research Program. Funded projects must have a set of quantifiable milestones for achievement that represent acceptable progress by the end of the first year.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Nebraska Medical Center
United States
Zip Code
Attri, Kuldeep S; Murthy, Divya; Singh, Pankaj K (2017) Racial disparity in metabolic regulation of cancer. Front Biosci (Landmark Ed) 22:1221-1246
Wu, Guangyin; Verma, Vivek; Haefner, Matthias F et al. (2017) Feasibility and reproducibility of substituting oral contrast with water for duodenal volume delineation in patients undergoing pancreatic stereotactic body radiotherapy. J Gastrointest Oncol 8:705-709
Verma, Vivek; Lazenby, Audrey J; Zheng, Dandan et al. (2017) Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial. Radiother Oncol 122:464-469
Karmakar, Saswati; Seshacharyulu, Parthasarathy; Lakshmanan, Imayavaramban et al. (2017) hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells. Oncotarget 8:14806-14820
Shukla, Surendra K; Purohit, Vinee; Mehla, Kamiya et al. (2017) MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Cancer Cell 32:71-87.e7
King, Ryan J; Yu, Fang; Singh, Pankaj K (2017) Genomic alterations in mucins across cancers. Oncotarget :
Krishn, Shiv Ram; Kaur, Sukhwinder; Sheinin, Yuri M et al. (2017) Mucins and associated O-glycans based immunoprofile for stratification of colorectal polyps: clinical implication for improved colon surveillance. Oncotarget 8:7025-7038
Gautam, Shailendra K; Kumar, Sushil; Cannon, Andrew et al. (2017) MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma. Expert Opin Ther Targets 21:657-669
Abrego, Jaime; Gunda, Venugopal; Vernucci, Enza et al. (2017) GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Lett 400:37-46
Souchek, Joshua J; Davis, Amanda L; Hill, Tanner K et al. (2017) Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells. Mol Cancer Ther 16:1819-1830

Showing the most recent 10 out of 163 publications